| 平兆幸.曲美他嗪联合美托洛尔治疗冠心病心力衰竭患者中的应用[J].中国现代医生,2021,59(20):51-53+57 |
| 曲美他嗪联合美托洛尔治疗冠心病心力衰竭患者中的应用 |
| Application of trimetazidine combined with metoprolol in the treatment of patients with coronary heart disease and heart failure |
| |
| DOI： |
| 中文关键词: 冠心病 心力衰竭 曲美他嗪 美托洛尔 心功能 生命体征 |
| 英文关键词:Coronary heart disease Heart failure Trimetazidine Metoprolol Cardiac function Vital signs |
| 基金项目: |
|
| 摘要点击次数: 2053 |
| 全文下载次数: 4502 |
| 中文摘要: |
| 目的 探讨曲美他嗪与美托洛尔联合治疗冠心病心力衰竭的临床疗效，为临床用药提供参考。方法 回顾性分析2017 年10 月至2019 年11 月我院收治冠心病心力衰竭患者（80 例）的临床资料，将单独使用美托洛尔治疗的40 例患者纳入对照组，将采用美托洛尔+曲美他嗪治疗的40 例患者纳入观察组。治疗前后分别比较两组患者心功能[左心室收缩末期内径（LVESD）、左心室舒张末内经（LEVDD）]指标水平与生命体征[舒张压（DBP）、收缩压（SBP）、心率（HR）]变化。结果 治疗前，观察组LVEDD、LVESD、LVEF 水平及SBP、DBP、HR 水平与对照组对比，差异无统计学意义（P＞0.05）；治疗3 个月后，观察组LVESD、LEVDD 水平[（53.24±2.47）mm、（34.15±2.25）mm]比对照组[（58.69±3.45）mm、（39.86±2.64）mm]更低，LVEF 水平[（49.96±3.36）%]比对照组[（44.16±3.15）%]更高，差异有统计学意义（t=8.124、10.411、7.965，P 均＜0.001）；观察组DBP、SBP、HR 水平[（114.37±11.16）mmHg、（75.98±7.64）mmHg、（83.54±8.78）次/min]均比对照组[（134.87±13.51）mmHg、（89.63±8.69）mmHg、（91.18±10.44）次/min]低，差异有统计学意义（t=7.399、7.457、3.542，P=0.000、0.000、0.001）。结论 冠心病心力衰竭患者服用曲美他嗪与美托洛尔两种药物治疗有助于促进患者身体恢复。 |
| 英文摘要: |
| Objective To investigate the clinical efficacy of trimetazidine combined with metoprolol in the treatment of coronary heart disease (CHD) and heart failure (HF)，and to provide a reference for the clinical medication.Methods The clinical data of 80 patients with CHD and HF admitted to our hospital from October 2017 to November 2019 were analyzed retrospectively.40 patients treated with metoprolol alone were included in the control group，and 40 patients treated with metoprolol and trimetazidine were included in the observation group.The changes in the levels of cardiac function [left ventricular end-systolic diameter (LVESD)，left ventricular end-diastolic dimension (LEVDD)] and vital signs [diastolic blood pressure (DBP)，systolic blood pressure (SBP)，heart rate (HR)] before and after treatment were compared between the two groups.Results Before treatment，the levels of LVEDD，LVESD，LVEF，SBP，DBP and HR in the observation group were not significantly different from those in the control group(P＞0.05).Three months after treatment，the levels of LVESD and LEVDD were lower in the observation group [(53.24±2.47) mm，(34.15±2.25) mm] than those in the control group [(58.69±3.45) mm，(39.86±2.64) mm]，LVEF level was higher in the observation group [(49.96±3.36)%] than that in the control group [(44.16±3.15)%]，with statistically significant differences(t=8.124，10.411，7.965，P＜0.001).The levels of DBP，SBP and HR were lower in the observation group [(114.37±11.16) mmHg，(75.98±7.64)mmHg，(83.54±8.78)beats/min] than those in the control group [(134.87±13.51) mmHg，(89.63±8.69) mmHg，(91.18±10.44) beats/min]，with statistically significant differences (t=7.399，7.457，3.542，P=0.000，0.000，0.001).Conclusion Trimetazidine and metoprolol are helpful to promote the recovery of patients with CHD and HF. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
